Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 939252

Neratinib after trastuzumab (T)-based adjuvant therapy in early- stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial

Martin Jimenez, M; Holmes, FA; Ejlertsen, B; Delaloge, S; Moy, B; Iwata, H; von Minckwitz, G; Chia, S; Mansi, J; Barrios, C et al.
Neratinib after trastuzumab (T)-based adjuvant therapy in early- stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial // Annals of Oncology / Andre, Fabrice (ur.).
Oxford: Oxford University Press, 2017. str. 43-44 doi:10.1093/annonc/mdx362 (poster, međunarodna recenzija, sažetak, ostalo)

CROSBI ID: 939252 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Neratinib after trastuzumab (T)-based adjuvant therapy in early- stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial

Autori
Martin Jimenez, M ; Holmes, FA ; Ejlertsen, B ; Delaloge, S ; Moy, B ; Iwata, H ; von Minckwitz, G ; Chia, S ; Mansi, J ; Barrios, C ; Gnant, M ; Tomasevic, Z ; Denduluri, N ; Separovic, R ; Kim, SB ; Jakobsen, EH ; Bryce, RP ; Xu, F ; Buyse, M ; Chan, A

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Izvornik
Annals of Oncology / Andre, Fabrice - Oxford : Oxford University Press, 2017, 43-44

Skup
42nd ESMO Congress (ESMO 2017)

Mjesto i datum
Madrid, Španjolska, 08.09.2017. - 12.09.2017

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
neratinib ; trastuzumab ; rani rak dojke ; ExteNET studija
(neratinib ; trastuzumab ; early-stage breast cancer ; ExteNET trial)

Sažetak
1 y of neratinib after T-based adjuvant therapy significantly improves iDFS at 5 y in pts with early-stage HER2+ BC, with a long-term sustained effect. A protocol-specified subgroup analysis suggested greater benefit in HR+ pts. Overall survival data are not yet mature.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA

Ustanove:
Klinika za tumore

Profili:

Avatar Url Robert Šeparović (autor)

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Martin Jimenez, M; Holmes, FA; Ejlertsen, B; Delaloge, S; Moy, B; Iwata, H; von Minckwitz, G; Chia, S; Mansi, J; Barrios, C et al.
Neratinib after trastuzumab (T)-based adjuvant therapy in early- stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial // Annals of Oncology / Andre, Fabrice (ur.).
Oxford: Oxford University Press, 2017. str. 43-44 doi:10.1093/annonc/mdx362 (poster, međunarodna recenzija, sažetak, ostalo)
Martin Jimenez, M., Holmes, F., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., von Minckwitz, G., Chia, S., Mansi, J. & Barrios, C. (2017) Neratinib after trastuzumab (T)-based adjuvant therapy in early- stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial. U: Andre, F. (ur.)Annals of Oncology doi:10.1093/annonc/mdx362.
@article{article, author = {Martin Jimenez, M and Holmes, FA and Ejlertsen, B and Delaloge, S and Moy, B and Iwata, H and von Minckwitz, G and Chia, S and Mansi, J and Barrios, C and Gnant, M and Tomasevic, Z and Denduluri, N and Separovic, R and Kim, SB and Jakobsen, EH and Bryce, RP and Xu, F and Buyse, M and Chan, A}, editor = {Andre, F.}, year = {2017}, pages = {43-44}, DOI = {10.1093/annonc/mdx362}, keywords = {neratinib, trastuzumab, rani rak dojke, ExteNET studija}, doi = {10.1093/annonc/mdx362}, title = {Neratinib after trastuzumab (T)-based adjuvant therapy in early- stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial}, keyword = {neratinib, trastuzumab, rani rak dojke, ExteNET studija}, publisher = {Oxford University Press}, publisherplace = {Madrid, \v{S}panjolska} }
@article{article, author = {Martin Jimenez, M and Holmes, FA and Ejlertsen, B and Delaloge, S and Moy, B and Iwata, H and von Minckwitz, G and Chia, S and Mansi, J and Barrios, C and Gnant, M and Tomasevic, Z and Denduluri, N and Separovic, R and Kim, SB and Jakobsen, EH and Bryce, RP and Xu, F and Buyse, M and Chan, A}, editor = {Andre, F.}, year = {2017}, pages = {43-44}, DOI = {10.1093/annonc/mdx362}, keywords = {neratinib, trastuzumab, early-stage breast cancer, ExteNET trial}, doi = {10.1093/annonc/mdx362}, title = {Neratinib after trastuzumab (T)-based adjuvant therapy in early- stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial}, keyword = {neratinib, trastuzumab, early-stage breast cancer, ExteNET trial}, publisher = {Oxford University Press}, publisherplace = {Madrid, \v{S}panjolska} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.